Millipore Sigma Vibrant Logo

PC67 Anti-Bcl-xL (Ab-1) (201-216) Rabbit pAb

Anti-Bcl-xL (Ab-1) (201-216) Rabbit pAb MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
PC67
  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
 
—
Request Pricing
—
Limited Availability Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

       

      Contact Customer Service

      Overview

      Replacement Information

      Key Spec Table

      Species ReactivityHostAntibody Type
      H, M, Op, RRbPolyclonal Antibody
      Description
      Overview

      This product has been discontinued.



      Recognizes the ~28 kDa Bcl-x protein in doxorubicin-treated MCF-7 cells.
      Catalogue NumberPC67
      Brand Family Calbiochem®
      Application Data
      Detection of human Bcl-x by immunoblotting. Sample: Whole cell lysate from MCF7 cells treated with doxorubicin (Cat. No. 324380) (200 ng/ml for 72 h). Primary antibody: Anti-Bcl-x (Ab-1) (201-216) Rabbit pAb (Cat. No. PC67) (lane 1) (2.5 µg/ml) and normal rabbit IgG, negative control (lane 2) (2.5 µg/ml). Detection: chemiluminescence.
      References
      ReferencesDatta R., et al. 1995. Cell Growth Differ 6, 363.
      Fang W., et al. 1995. J. Immunol. 155, 66.
      Gonzalez-Garcia M., et al. 1994. Development 120, 3033.
      Krajewski S., et al. 1994. Cancer Res 54, 5501.
      Boise L.H., et al. 1993. Cell 74, 597.
      Product Information
      FormLiquid
      FormulationIn 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.
      Negative controlBrain tissue
      Positive controlDoxorybicin-treated MCF-7 cells (see comments) or intestinal tissue
      Preservative≤0.1% sodium azide
      Quality LevelMQ100
      Applications
      Key Applications Frozen Sections
      Immunoblotting (Western Blotting)
      Paraffin Sections
      Application NotesFrozen Sections (5 µg/ml)
      Immunoblotting (2.5 µg/ml, chemiluminescence)
      Paraffin Sections (2.5 µg/ml, pressure cooker pre-treatment required)
      Application CommentsThe immunoblotting application applies to human samples only. Mouse and rat frozen intestinal tissue was fixed with Zamboni's fixative prior to staining. Only random cells will stain for bcl-x in brain tissue. For MCF-7 cells as a positive control, stimulate for 72 h with 0.2 µg/ml doxorubicin. The immunogen sequence is present only in the long form of Bcl-x. Antibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogena synthetic peptide (PWIQENGGWDTFVELY) corresponding to amino acids 201-216 of human Bcl-x
      ImmunogenHuman
      HostRabbit
      IsotypeIgG
      Species Reactivity
      • Human
      • Mouse
      • Opossum
      • Rat
      Antibody TypePolyclonal Antibody
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Do not freeze Yes
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      PC67 0

      Documentation

      Anti-Bcl-xL (Ab-1) (201-216) Rabbit pAb MSDS

      Title

      Safety Data Sheet (SDS) 

      Anti-Bcl-xL (Ab-1) (201-216) Rabbit pAb Certificates of Analysis

      TitleLot Number
      PC67

      References

      Reference overview
      Datta R., et al. 1995. Cell Growth Differ 6, 363.
      Fang W., et al. 1995. J. Immunol. 155, 66.
      Gonzalez-Garcia M., et al. 1994. Development 120, 3033.
      Krajewski S., et al. 1994. Cancer Res 54, 5501.
      Boise L.H., et al. 1993. Cell 74, 597.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision15-October-2007 RFH
      ApplicationFrozen Sections (5 µg/ml)
      Immunoblotting (2.5 µg/ml, chemiluminescence)
      Paraffin Sections (2.5 µg/ml, pressure cooker pre-treatment required)
      Application Data
      Detection of human Bcl-x by immunoblotting. Sample: Whole cell lysate from MCF7 cells treated with doxorubicin (Cat. No. 324380) (200 ng/ml for 72 h). Primary antibody: Anti-Bcl-x (Ab-1) (201-216) Rabbit pAb (Cat. No. PC67) (lane 1) (2.5 µg/ml) and normal rabbit IgG, negative control (lane 2) (2.5 µg/ml). Detection: chemiluminescence.
      DescriptionPurified rabbit polyclonal antibody. Recognizes the ~28 kDa Bcl-x protein.
      Backgroundbcl-x is a bcl-2-related gene that can function as a regulator of programmed cell death (apoptosis) independent of bcl-2. Alternative splicing results in two distinct bcl-x mRNAs, bcl-xL and bcl-xS. The larger mRNA gives rise to a protein product, bcl-xL, which is similar in size and predicted structure to bcl-2. bcl-x immunoreactivity has been detected in a wide variety of cell types and the protein is typically present in the cytosol in association with the mitochondrial periphery, a property shared with bcl-2. Of the two isoforms of bcl-x, the long (bcl-xL) is the most abundant mRNA species expressed in embryonic and adult tissues and most likely differs from bcl-2 in its regulatory activity on cell differentiation through controlled tissue specific expression. Like its homolog bcl-2, the mechanism and extent of bcl-x's function are still increasing. bcl-xL has been shown to modify the cell's response to oxidants as well as to participate in resistance to chemotherapeutic agents and radiation.
      HostRabbit
      Immunogen speciesHuman
      Immunogena synthetic peptide (PWIQENGGWDTFVELY) corresponding to amino acids 201-216 of human Bcl-x
      IsotypeIgG
      Specieshuman, mouse, opossum, rat
      Positive controlDoxorybicin-treated MCF-7 cells (see comments) or intestinal tissue
      Negative controlBrain tissue
      FormLiquid
      FormulationIn 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.
      Concentration Label Please refer to vial label for lot-specific concentration
      Preservative≤0.1% sodium azide
      CommentsThe immunoblotting application applies to human samples only. Mouse and rat frozen intestinal tissue was fixed with Zamboni's fixative prior to staining. Only random cells will stain for bcl-x in brain tissue. For MCF-7 cells as a positive control, stimulate for 72 h with 0.2 µg/ml doxorubicin. The immunogen sequence is present only in the long form of Bcl-x. Antibody should be titrated for optimal results in individual systems.
      Storage +2°C to +8°C
      Do Not Freeze Yes
      Toxicity Standard Handling
      ReferencesDatta R., et al. 1995. Cell Growth Differ 6, 363.
      Fang W., et al. 1995. J. Immunol. 155, 66.
      Gonzalez-Garcia M., et al. 1994. Development 120, 3033.
      Krajewski S., et al. 1994. Cancer Res 54, 5501.
      Boise L.H., et al. 1993. Cell 74, 597.